Larson Financial Group’s Outlook Therapeutics OTLK Stock Holding History

Larson Financial Group’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159	Hold	100	–	–	﹤0.01%	3620
2026 Q1	$21	Hold	100	–	–	﹤0.01%	3582
2025 Q4	$158	Hold	100	–	–	﹤0.01%	3306
2025 Q3	$106	Hold	100	–	–	﹤0.01%	3322
2025 Q2	$160	Hold	100	–	–	﹤0.01%	3097
2025 Q1	$122	Hold	100	–	–	﹤0.01%	2881
2024 Q4	$189	Hold	100	–	–	﹤0.01%	2456
2024 Q3	$534	Hold	100	–	–	﹤0.01%	2111
2024 Q2	$738	Hold	100	–	–	﹤0.01%	1769
2024 Q1	$1.19K	Hold	100	–	–	﹤0.01%	1427
2023 Q4	$788	Hold	100	–	–	﹤0.01%	1510
2023 Q3	$442	Hold	100	–	–	﹤0.01%	1587
2023 Q2	$3.48K	Hold	100	–	–	﹤0.01%	1171
2023 Q1	$2.18K	Hold	100	–	–	﹤0.01%	1231
2022 Q4	$2.16K	Buy	+100	New	+$2.17K	﹤0.01%	1181

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

Larson Financial Group's OTLK Position: Q2 2026 in Review

Larson Financial Group held its Outlook Therapeutics (OTLK) position steady in Q2 2026 at 100 shares worth $159. The position accounts for ﹤0.01% of the portfolio, ranked #3620.

Larson Financial Group first reported a position in OTLK in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.48K in Q2 2023. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Larson Financial Group held 100 shares of Outlook Therapeutics worth $159 as of Q2 2026.
Larson Financial Group left its Outlook Therapeutics share count unchanged in Q2 2026.
Outlook Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3620 holding.
Larson Financial Group first reported a position in Outlook Therapeutics in Q4 2022 and has held it in 15 quarters since.
Larson Financial Group's Outlook Therapeutics position peaked at $3.48K in Q2 2023.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.